Diagnosis of immunodeficiency or is receiving treatment with systemic steroid therapy or any other form of immunosuppressive therapy within seven days prior to registration for protocol therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids (up to 7.5mg/d of prednisone or equivalent) may be approved after consultation with the sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency, is receiving systemic steroid therapy (except for physiological dose levels), or immunosuppressive therapiesXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg of prednisone or equivalent) or any other form of immunosuppressive therapy (including immune modulators or systemic corticosteroids) that cannot be discontinued safely within 14 days prior to study enrollmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of AMG 757Xx_NEWLINE_xXIs receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXA diagnosis of immunodeficiency or is currently receiving systemic steroid therapy at any dose or is receiving any other form of immunosuppressive therapy; steroid therapy is not allowed within 7 days prior to the first dose of trial treatment; however, topical and intranasal corticosteroids are allowed, and not an exclusion for participationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy =< 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXPatient has a diagnosis of immunodeficiency, or is receiving systemic steroid therapy (> 10 mg prednisone daily, or steroid equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of avelumabXx_NEWLINE_xXCOHORT 1: Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXCOHORT 2: Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXSAFETY RUN-IN: Diagnosis of immunosuppression or receiving steroid therapy or other immunosuppressive therapy within 4 weeks of the studyXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Diagnosis of immunosuppression or receiving steroid therapy or other immunosuppressive therapy within 4 weeks of the studyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy in excess of replacement doses, or on any other form of immunosuppressive medication.Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving either systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of trial drug.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study therapyXx_NEWLINE_xXAny systemic steroid therapy or other form of immunosuppressive therapy within 7 days of the first dose of mRNA-4157 or pembrolizumabXx_NEWLINE_xXIs receiving systemic steroid therapy ?7 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medicationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (i.e., doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study therapyXx_NEWLINE_xXAny diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days of initiation of therapyXx_NEWLINE_xXPatients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to registration are not eligibleXx_NEWLINE_xXMust not have a diagnosis of immunodeficiency, or receiving systemic steroid therapy, or any other form of immunosuppressive therapy within 7 days prior to trial treatment; short burst of steroids of 5-7 days (for chronic obstructive pulmonary disease [COPD] exacerbation or other similar indication) are allowedXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy (other than oral contraceptives) or any other form of immunosuppressive therapy within 7 days prior to registrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy that exceeds a maximum amount of 10 mg of prednisone/day or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration.Xx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the date of allocation/randomizationXx_NEWLINE_xXPatients receiving systemic steroid therapy or any other systemic immunosuppressive medication. Local steroid therapies are acceptableXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXSystemic steroid therapy or any immunosuppressive therapyXx_NEWLINE_xXSystemic steroid or other immunosuppressive therapy within 4 weeks of starting the studyXx_NEWLINE_xXOngoing treatment with steroid therapy or other immunosuppressiveXx_NEWLINE_xXPatient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumabXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of HiDAC treatment; NOTE: use of steroid eye drops starting at the time of HiDAC administration is allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy for purposes of immunosuppression or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or immunosuppressive therapy within 7 days prior to planned first dose of trial treatment.Xx_NEWLINE_xXHas a known diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumabXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (with the exception of daily dexamethasone =< 4 mg)Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of MK-3475Xx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.Xx_NEWLINE_xXSystemic therapy with immunosuppressive agents within 7 days before enrollmentXx_NEWLINE_xXConcurrent systemic steroid therapy.Xx_NEWLINE_xXHas received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency that requires receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment or has resulted in life threatening episodes previously regardless of current treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; physiologic doses of steroid therapy (? 2 mg/day dexamethasone equivalents) by the time of first dose of treatment are allowedXx_NEWLINE_xXSystemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to registrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceiving immunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment therapy;\r\n* NOTE: Systemic steroid doses of ? 10 mg of prednisone daily or its equivalent are allowed in patients receiving physiologic replacement steroid dosesXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, except for physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency which is permittedXx_NEWLINE_xXHas a known diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.Xx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of the study drugXx_NEWLINE_xXMedical condition that requires chronic systemic steroid therapy, or any other form of immunosuppressive medicationXx_NEWLINE_xXAny diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days of initiation of therapyXx_NEWLINE_xXReceiving systemic steroid therapy or any form of immunosuppressive therapy within 1 week prior to the start of study drugXx_NEWLINE_xXAny diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days of initiation of therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency, or is receiving systemic steroid therapy above physiologic replacement dose, or any other form of immunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXMust have been off immunosuppressive therapy for >= 7 days before receiving first dose of pembrolizumabXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency, is receiving systemic steroids above physiologic dose (> 10 mg/day prednisone or equivalent) within 7 days of start of therapy or is receiving any other form of immunosuppressive therapy.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to on-study dateXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose greater than 10 mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy > 10 mg/day or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment; topical, inhaled, ocular, and intra-articular steroids are not exclusionaryXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy =< 7 days prior to registrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or receiving steroid therapy of any other form of immunosuppressive therapy within 7 days prior to first dose of trial treatment; subjects who receive daily steroid replacement therapy serve as an exception to this rule; daily prednisone at doses of 5 to 7.5 mg (or hydrocortisone equivalent doses) is an example of replacement therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy equivalent to >= 10 mg/day of prednisone, or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunosuppression or receiving steroid therapy or other immunosuppressive therapy within 4 weeks of the studyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of physiologic dose or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or exposure to systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (nasal or oral inhalers are permissible)Xx_NEWLINE_xXPatient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy(> 10 mg prednisone daily, or steroid equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumabXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\r\n* Short-term administration of systemic steroids (i.e., for allergic reactions or the management of immune related adverse events [irAEs]) is allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to registrationXx_NEWLINE_xXConditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment, with the exception of steroids for adrenal insufficiency in which case prednisone =< 10 mg/day or its equivalent is allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXSubjects must not be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to the first dose of study medication; the use of physiologic doses of corticosteroids is acceptableXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or any other form of immunosuppressive therapy.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, patients with human immunodeficiency virus (HIV) adequately controlled on antiretrovirals (undetectable viral load) and patients with chronic lymphocytic leukemia (CLL) not requiring systemic treatment will be included; in addition, steroids for physiologic replacement will be allowed (must be equal to or less than 10mg of prednisone/day)Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids may be approved after consultation with the sponsorXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids may be approved after consultation with the principal investigator (PI) and MerckXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids (prednisone 10 mg or equivalent) may be approved after consultation with the sponsorXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXIs receiving systemic steroid therapy within three days prior to the first dose of trial treatment or receiving any other form of immunosuppressive medication (corticosteroid use on study for management of early combined immunosuppression [ECIs] is allowed)Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment or, is taking any other medication that might affect immune functionXx_NEWLINE_xXSubjects who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the initiation of SBRTXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXImmunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXSystemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHistory of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study drug administrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment during the neoadjuvant pembrolizumab and optional adjuvant pembrolizumab stagesXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; inhaled and topical steroids are allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids for adrenal and pituitary insufficiency is not considered a form of systemic steroid therapy and would not exclude a subject from the studyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic immunosuppressive therapy within 7 days of study entranceXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumabXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of MK-3475Xx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a known history of immunosuppression or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 daysXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiation of lymphodepletion; exception: patients on chronic physiologic dose of steroid equivalent to prednisone < 10 mg/day is allowedXx_NEWLINE_xXSystemic steroid therapy or immunosuppressive therapy within 14 days before vaccine administrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; unless the steroid therapy is for physiological replacementXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXSubject has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; with the exception of physiologic steroid replacementXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or exposure to systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (nasal or oral inhalers are permissible)Xx_NEWLINE_xXSubject has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXOn chronic systemic steroid therapy in excess of replacement doses, or on any other form of immunosuppressive medicationXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXSystemic or topical steroid use or other immunosuppressive therapy within the past 14 daysXx_NEWLINE_xXPatient has a diagnosis of immunodeficiency or is receiving ongoing immunosuppressive therapy, including systemic or enteric corticosteroids except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary disease, allergic rhinitis). Patient must be off systemic steroid or any other form of immunosuppressive therapy within 7 days prior to first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy > 10 mg prednisone or equivalent per day or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment;Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of prednisone 10 mg/24 h equivalent, or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of protocol specified therapy.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to randomizationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patient must not have a diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatmentXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Patient must not have a diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving any systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to day 1 of trial treatmentXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis now or in the past of immunodeficiency requiring systemic steroid therapy in excess of physiologic dose (or any other form of immunosuppressive therapy within 10 days prior to the first dose of trial treatment)Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; inhaled or topical steroids are allowedXx_NEWLINE_xXHas received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to registration for protocol therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving any systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Day 1 of trial treatment.Xx_NEWLINE_xXDiagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy =< 7 days prior to registrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy; the use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI)Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXAny diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days of initiation of therapyXx_NEWLINE_xXParticipants with a diagnosis of immunodeficiency or who are receiving systemic steroid therapy (>= than 5 mg prednisone or its equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment; physiologic doses of steroid therapy (=< 10 mg/day prednisone equivalents) is allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks of the first protocol treatment; the use of low-dose steroids for management of chronic conditions is allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic immunosuppressive steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment; exception: physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is not considered systemic immunosuppressive steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency (including organ grafts and human immunodeficiency virus [HIV]), or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug (exceptions: nasal corticosteroids, inhaled steroids, adrenal replacement steroids and steroid creams are allowed)Xx_NEWLINE_xXReceiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., limited low-dose dexamethasone for nausea, multiple doses for contrast allergy) may be enrolled in the study and would not require a 7 day washoutXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunosuppressive disorder OR is on any other form of immunosuppressive therapy within 7 days prior to transplant admissionXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization on this studyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to treatment allocationXx_NEWLINE_xXIs receiving systemic steroid therapy <3 days before the first dose of study drug or receiving any other form of immunosuppressive medication.Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medicationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.Xx_NEWLINE_xXImmunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXDiagnosed with immunodeficiency or receiving systemic steroid therapy or another form of immunosuppressive therapy within 7 daysXx_NEWLINE_xXActive systemic immunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency OR is receiving a systemic steroid therapy exceeding 10 mg daily dose of prednisone or equivalent or any other form of immunosuppressive therapy within 7 days prior to allocation, except in the case of central nervous system (CNS) metastases (see below).Xx_NEWLINE_xXReceiving TNF pathway inhibitors, PI3 kinase inhibitors, systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXHas a diagnosis of immunodeficiency OR is receiving a systemic steroid therapy exceeding physiologic corticosteroid dose or any other form of immunosuppressive therapy within 7 days prior to randomization, except in the case of central nervous system (CNS) metastases.Xx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXSubject is on any systemic steroid therapy, within one week before the planned date for first dose of study treatment. Subject is on any other form of immunosuppressive medicationXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within seven days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.Xx_NEWLINE_xXReceiving immunosuppressive therapyXx_NEWLINE_xXIs on chronic systemic steroid therapy or on any other form of immunosuppressive medicationXx_NEWLINE_xXReceiving TNF pathway inhibitors, PI3 kinase inhibitors, systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the planned first dose of the studyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXImmunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving any systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Day 1 of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment; physiologic doses of steroid therapy (=< 10 mg/day prednisone equivalents) is allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXReceiving systemic steroid therapy <= 3 days prior to first dose of study drug or receiving any other form of immunosuppressive medicationXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugXx_NEWLINE_xXReceiving systemic steroid therapy within 3 days prior to the first dose of study treatment or receiving any other form of immunosuppressive medicationXx_NEWLINE_xXChronic systemic steroid therapy or on any other form of immunosuppressive medicationXx_NEWLINE_xXFor cohort 2, received > 30 days of prior treatment with CDK4/6 inhibitors or > 60 days of letrozole before screening diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXWithin 7 days prior to the planned start of study treatment:\r\n* Is receiving systemic steroid therapy or any other form of immunosuppressive therapyXx_NEWLINE_xXPatients receiving systemic treatment with systemic steroid therapy or any other immunosuppressive medication at any dose level that would interfere with the action of the study drugs in the opinion of the investigatorXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, exceptions include topical, intralesional, intraarticular and inhaled steroids; a pulse steroid dose prior to and after imaging to prevent contrast allergy in patients with known allergy to contrast is allowedXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy in dosing exceeding 10 mg daily of prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.Xx_NEWLINE_xXDiagnosis of immunosuppression or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of' immunosuppressive therapy within 7 days prior to the first dose of trial treatment.Xx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXSystemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication (physiologic doses of corticosteroids may be approved after consultation with the Sponsor)Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy > 2 mg of dexamethasone total per day or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the radiation therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids may be approved after consultation with the sponsorXx_NEWLINE_xXHas a diagnosis of immunodeficiency (HIV) or is receiving systemic steroid therapy (in excess of 20 mg of prednisone daily) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\r\n* Note: dexamethasone prior to treatment on day 1 of each treatment cycle is allowedXx_NEWLINE_xXPatient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of trial treatmentXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medicationXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial medicationXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapyXx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXAny condition requiring active steroid or other immunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomizationXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment, or has a history of organ transplant, including allogeneic stem cell transplantXx_NEWLINE_xXSubject is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy by oral or IV routes within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (i.e., dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXConcurrent systemic or inhaled steroid therapyXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXSystemic steroids, any other form of immunosuppressive therapy or radiation therapy within 14 days prior to registration.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7 days prior to the first dose of trial treatment; individuals who are receiving systemic steroid therapy at a stable dose less than or equal to 10mg of prednisone per day or its equivalent will be permitted to participateXx_NEWLINE_xXIs on chronic systemic steroid therapy in excess of replacement doses, or on any other form of immunosuppressive medicationXx_NEWLINE_xXknown diagnosis of immunodeficiency or is receiving systemic steroid therapy or other form of immunosuppressive therapy within 7 days of clinical trial treatment.Xx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor.Xx_NEWLINE_xXDiagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy (including immune modulators or systemic corticosteroids) within 7 days prior to study enrollment.Xx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving therapeutic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXSystemic steroid or other immunosuppressive therapy within 4 weeks of starting the studyXx_NEWLINE_xXOn immunosuppressive therapy.Xx_NEWLINE_xXKnown diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXKnown diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXSystemic steroid therapy requirementXx_NEWLINE_xXReceiving immunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to day 1Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXConcurrent systemic steroid therapyXx_NEWLINE_xXDiagnosis of immunosuppression or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids may be approved after consultation with the sponsorXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (> 10 mg of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatmentXx_NEWLINE_xXPatient on steroid therapyXx_NEWLINE_xXSubjects on chronic steroid therapy, other immunosuppressive therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to C11-AMT PET scanXx_NEWLINE_xXReceiving systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to first injection of [18F]F-AraG\r\n* Topical and inhaled corticosteroids are allowedXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy =< 7 days prior to registrationXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior the first dose of study treatment.Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy =< 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; subjects requiring systemic steroids are excluded from the trial; the use of physiologic doses of corticosteroids may be approved after discussion with the sponsorXx_NEWLINE_xXIs on chronic systemic steroid therapy in excess of replacement doses or on any other form of immunosuppressive medication.Xx_NEWLINE_xXPatients may not have a need for chronic systemic steroid therapyXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; subjects requiring systemic steroids are excluded from the trial; the use of physiologic doses of corticosteroids may be approved after discussion with the sponsorXx_NEWLINE_xXDiagnosis of immunosuppression or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment . The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunosuppression or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy (other than oral contraceptives) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentXx_NEWLINE_xX